Efficacy and safety analysis of domestic dasatinib as second-line treatment for pediatric adolescents with chronic myeloid leukemia in chronic phase
Objective:To investigate the efficacy and safety of domestic dasatinib as second-line treatment for pediatric adolescents with chronic myeloid leukemia in chronic phase(CML-CP).Methods:A retrospective analy-sis of clinical data of CML-CP pediatric adolescents who received domestic dasatinib as second-line treatment in the Henan Tumor Hospital from August 2016 to September 2021 was performed.The optimal response rate at 3,6 and 12 months,the cumulative rates of complete cytogenetic response and major molecular responses,the rates of progression free survival and event free survival,adverse events of the patients were assessed.Results:A total of 29 patients were enrolled in this study.The median follow-up time was 26(12-75)months.The optimal response rates at 3,6 and 12 months were 82.8％(24/29),93.1％(27/29),86.2％(25/29),respectively.By the end of follow-up,the cumulative rates of complete cytogenetic response and major molecular response were 86.2％(25/29)and 65.5％(19/29),respectively.During follow-up,the rates of progression free survival and event free sur-vival were 100.0％(29/29)and 82.8％(24/29),respectively.The most common non-hematological adverse e-vents of dasatinib were elevated transaminase level(10.3％)and rash(10.3％).The common hematological ad-verse events of dasatinib were anemia(24.1％)and thrombocytopenia(6.9％).Conclusion:Domestic dasatinib is effective and safe as the second-line treatment of CML-CP pediatric adolescents and can be a good choice.
NETL
NSTL
万方数据
